The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review.

Copson, E and Shaaban, A M and Maishman, T and Moseley, P M and McKenzie, H and Bradbury, J and Borley, A and Brzezinska, M and Chan, S Y T and Ching, J and Cutress, R I and Danial, I and Dall, B and Kerin, M and Lowery, A J and Macpherson, I R and Romics, L and Sawyer, E and Sharmat, N and Sircar, T and Vidya, R and Pan, Y and Rea, D and Jones, L and Eccles, D M and Berditchevski, F (2018) The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review. Breast (Edinburgh, Scotland), 42. pp. 133-141. ISSN 1532-3080. This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs

Full text not available from this repository.
Official URL: https://www.thebreastonline.com/article/S0960-9776...

Abstract

OBJECTIVES

Inflammatory Breast cancer (IBC) is a rare but aggressive form of breast cancer. Its incidence and behaviour in the UK is poorly characterised. We collected retrospective data from hospitals in the UK and Ireland to describe the presentation, pathology, treatment and clinical course of IBC in the UK.

MATERIALS AND METHODS

Patients with IBC diagnosed between 1997-2014 at fourteen UK and Irish hospitals were identified from local breast unit databases. Patient characteristics, tumour pathology and stage, and details of surgical, systemic and radiotherapy treatment and follow-up data were collected from electronic patient records and medical notes.

RESULT

This retrospective review identified 445 patients with IBC accounting for 0.4-1.8% of invasive breast cancer cases. Median follow-up was 4.2 years. 53.2% of tumours were grade 3, 56.2% were oestrogen receptor positive, 31.3% were HER2 positive and 25.1% were triple negative. 20.7% of patients had distant metastases at presentation. Despite trimodality treatment in 86.4%, 40.1% of stage III patients developed distant metastases. Five-year overall survival (OS) was 61.0% for stage III and 21.4% for stage IV patients.

CONCLUSIONS

This is the largest series of UK IBC patients reported to date. It indicates a lower incidence than in American series, but confirms that IBC has a high risk of recurrence with poor survival despite contemporary multi-modality therapy. A national strategy is required to facilitate translational research into this aggressive disease.

Item Type: Article
Additional Information: This article is available to all UHB staff and students via ASK Discovery tool http://tinyurl.com/z795c8c by using their UHB Athens login IDs
Subjects: QZ Pathology. Oncology
WP Gynaecology. Women’s health
Divisions: Clinical Support > Pathology
Related URLs:
Depositing User: Miss Emily Johnson
Date Deposited: 24 May 2019 15:01
Last Modified: 24 May 2019 15:01
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/2110

Actions (login required)

View Item View Item